BiOpticROCO:6850 92 Days Payable is 20.73 as of Dec. 2025, which is 67% below its 10-year median of 63.02. GuruFocus rates ROCO:6850 with a GF Score™ of 92/100 and a GF Value™ of NT$44.91 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 701 Biotechnology companies, BiOptic ranks worse than 85.88% on this metric.
BiOptic's average Accounts Payable for the
six
months ended in Dec. 2025 was NT$6.3 Mil. BiOptic's Cost of Goods Sold for the
six
months ended in Dec. 2025 was NT$55.2 Mil.
Hence, BiOptic's Days Payable for the
six
months ended in Dec. 2025 was 20.73.
The historical rank and industry rank for BiOptic's Days Payable or its related term are showing as below:
ROCO:6850'
s Days Payable Range Over the Past 10 Years
Min: 21.9 Med: 63.02 Max: 160.63
Current: 24.08
During the past 8 years, BiOptic's highest Days Payable was 160.63. The lowest was 21.90. And the median was 63.02.
ROCO:6850's Days Payable is ranked worse than 85.88% of 701
companies
in the Biotechnology industry
Industry Median: 112.84
vs ROCO:6850: 24.08
BiOptic's Days Payable
declined
from Dec. 2024 (30.93) to Dec. 2025 (20.73).
It may suggest that BiOpticaccelerated paying its suppliers.
BiOptic Days Payable Related Terms
BiOptic Days Payable Historical Data
* Premium members only.
The historical data trend for BiOptic's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6850 vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, BiOptic's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BiOptic Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BiOptic's Days Payable distribution charts can be found below:
* The bar in red indicates where BiOptic's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
BiOptic's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BiOptic (ROCO:6850) has a Days Payable of 20.73 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on BiOptic and its competitors. This is 67% below median its historical median of 63.02. Over the past decade, BiOptic's Days Payable has ranged from 21.90 to 160.63. According to the industry distribution chart, BiOptic ranks #602 out of 701 companies in the Biotechnology industry, placing it in the top 85.9%.
Is BiOptic's Days Payable too high?
BiOptic's current Days Payable of 20.73 is 67% below median its 10-year median of 63.02. Over the past 10 years, this metric has ranged from a low of 21.90 to a high of 160.63. The Biotechnology industry median Days Payable is 112.84. BiOptic's value of 20.73 is 81.6% below this industry median. Based on the distribution chart, BiOptic ranks #602 out of 701 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BiOptic has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BiOptic's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BiOptic ranks #602 out of 701 companies for Days Payable. This places BiOptic in the lower half of its industry. The industry median Days Payable is 112.84. BiOptic's value of 20.73 is 81.6% below this benchmark. Historically, BiOptic's own Days Payable has ranged from 21.90 to 160.63 over the past decade. While the company's 10-year median is 63.02 vs. the industry median of 112.84, BiOptic has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.84, based on 701 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BiOptic's current Days Payable of 20.73 is 81.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on BiOptic and its competitors. For the Biotechnology industry, the median Days Payable is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BiOptic's current Days Payable is 20.73, which is 67% below median its own 10-year median of 63.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BiOptic stock overvalued right now?
Based on GuruFocus' analysis, BiOptic (ROCO:6850) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$44.91, compared to a current price of NT$35.00 — trading 22.1% below its estimated fair value. The current Days Payable is 20.73, which is 67% below median its 10-year median of 63.02 and 81.6% below the Biotechnology industry median of 112.84. BiOptic's overall GF Score™ is 92/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For BiOptic (ROCO:6850), the current Days Payable is 20.73 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BiOptic (ROCO:6850) Overvalued in 2026?
Based on GuruFocus' analysis, BiOptic stock appears to be undervalued.
The current stock price of NT$35.00 is trading 22.1% below its estimated GF Value™ of NT$44.91.
GuruFocus considers BiOptic to be Modestly Undervalued.
Key valuation signals for ROCO:6850:
Days Payable: 20.73 (67% below median its 10-year median of 63.02)
GF Value™: NT$44.91 vs. price of NT$35.00 (22.1% below fair value)
Industry Position: 81.6% below the Biotechnology median (#602 of 701)
No single metric tells the full story. See the ROCO:6850 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BiOptic Inc is a biotechnology instrumentation company that develops scientific products for research and clinical applications. It serves professionals and laboratories dedicated to life science research, clinical diagnostics, pharmaceutical and food industries, animal husbandry, and agriculture, performing diagnostic molecular genetic analyses.
92GF Score
Get the complete analysis for ROCO:6850
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6850 has been successfully added to your 
